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Abstract
Background: Despite the dramatically improved survival due to combination antiretroviral therapies (cART), life
expectancy of people with HIV/AIDS remains lower than that of the general population. This study aimed to
estimate, at a population level, the survival experience of Italian people with AIDS (PWA) and to quantify the
prognostic role of selected factors at diagnosis in the risk of early mortality (i.e., within six months from AIDS
diagnosis).
Methods: A population-based, retrospective-cohort study was conducted among Italian PWA diagnosed between
1999 and 2009 and recorded in the national AIDS registry. The vital status, up to December 2010, of 14,552 PWA was
ascertained through a record linkage procedure with the Italian mortality database. Survival probabilities were
estimated through Kaplan-Meier method. To identify risk factors for early mortality from any cause, odds ratios (ORs)
and corresponding 95 % confidence intervals (CIs), adjusted for major confounders, were computed using multivariate
logistic regression models.
Results: Of the 5,706 deaths registered among the 14,552 PWA included in the study, 2,757 (18.9 %) occurred within
six months from AIDS diagnosis. The probability of surviving six months increased from 81.2 % in PWA diagnosed in
1999–2000 to 82.9 % in 2009, while the 5-year survival augmented from 60.7 % in PWA diagnosed in 1999–2000 to
65.4 % for PWA diagnosed in 2005–2006. Elevated risks of early mortality were associated to older age (OR = 5.28;
95 % CI: 4.41-6.32 for age ≥60 vs. <35 years), injecting drug use (OR = 1.71; 95 % CI: 1.53-1.91 vs. heterosexual
intercourse), and CD4 count <50 cells/mm3 at AIDS diagnosis (OR = 1.87, 95 % CI: 1.55-2.27 vs. ≥350). Elevated ORs
for early mortality also emerged for PWA diagnosed with primary brain lymphoma (OR = 11.66, 95 % CI: 7.32-18.57), or
progressive multifocal leukoencephalopathy (OR = 4.21, 95 % CI: 3.37-5.27).
Conclusions: Our study documented, among Italian PWA, the high - though slightly decreasing - frequency of early
mortality in the full cART era. These findings indicate the need for enduring and ameliorating preventive actions aimed
at timely HIV testing among all individuals at risk for HIV infection and/or those who present diseases known to be
related with HIV infection.
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Background
Development of combination antiretroviral therapies
(cART) in the mid-1990s revolutionized the care of HIV-
infected patients, leading to a marked decline in morbidity
and mortality associated with HIV infection [1]. Although
the increasingly widespread use of cART has substantially
improved the survival of HIV-infected people who have
access to these drugs [2], at a population level the life ex-
pectancy of HIV-infected people is still lower than that
observed in the general population [3].
The yearly number of new AIDS diagnoses recorded
by the Italian national AIDS registry (RNAIDS) has
steadily decreased in the last decade almost halving its
total, i.e., from nearly 2,000 cases in 2000 to approxi-
mately 1,000 cases in 2011–2013 [4]. In Italy, cART for
HIV-infected individuals is free of charge and adminis-
tered according to regularly updated standardized guide-
lines [5]. Nonetheless, some factors, such as late HIV
diagnosis, can delay access to cART and have an impact
on life expectancy of AIDS patients [6]. A previous study
on Italian people with AIDS (PWA) reported that mor-
tality was particularly elevated, as compared to the gen-
eral population, during the first year following AIDS
diagnosis [7].
The present epidemiological study intended to esti-
mate, at a population level, the survival of Italian PWA
in the cART era and to quantify the prognostic role of
selected factors at diagnosis on the risk of early mortality
(i.e., herein defined as death within six months following
AIDS diagnosis).
Methods
A population-based, retrospective-cohort study was con-
ducted among Italian PWA diagnosed between 1999 and
2009 and reported to the RNAIDS. In Italy, AIDS diag-
noses (based on clinical criteria in accordance with the
1993 revised European AIDS definition [8]) are compul-
sorily reported to the RNAIDS, a national surveillance
system previously described in detail [4]. For the present
analysis, the following information collected at AIDS
diagnosis by the RNAIDS was used: age, gender, area of
residence, years of education, HIV transmission mode
[mutually exclusive groups: injecting drug use (IDU),
heterosexual intercourse, homosexual male intercourse],
year of diagnosis, CD4 cell count, use of cART before
AIDS, date of first HIV-positive test, and AIDS-defining
diseases. AIDS-defining diseases were classified into: i)
infectious diseases (Pneumocystis carinii pneumonia, tu-
berculosis, candidiasis, recurrent pneumonia, brain toxo-
plasmosis, other opportunistic infections); ii) neoplasms
(invasive cervical cancer, Kaposi sarcoma, immunoblastic
lymphoma, Burkitt lymphoma, primary brain lymph-
oma); and iii) other conditions (HIV encephalopathy,
HIV wasting syndrome, and progressive multifocal
leukoencephalopathy). Individuals with more than one
AIDS-defining disease were assigned to the condition
with the worst prognosis [7].
The vital status of PWA (as of December 31, 2010)
was provided by the Italian National Institute of Statis-
tics (ISTAT), where death certificates from the whole na-
tional territory are centrally collected and electronically
stored in the Italian mortality database. Death certificate
registration is mandatory (with completeness being around
100 %) and since January 1999, the ISTAT database of
death certificates is managed according to European guide-
lines [9–11], and it includes names and surnames. In
agreement with the national law regulating the use of sens-
ible data, we carried out a record linkage between the
RNAIDS and the Italian mortality database following the
inclusion, in 2012, of this study in the National Statistical
Plan and the consequent authorization of the Italian Data
Protection Authority. The record linkage was performed
using an upgraded version of Software for Automated
Linkage in Italy (SALI), a software application developed
and validated in Italy to identify the same individuals in
two different databases ensuring anonymity through a
blinded procedure [7, 12].
Data regarding the 17,969 PWA reported to the
RNAIDS from 1999 to 2009 were linked to data con-
cerning the 6,895,720 deaths reported to the Italian mor-
tality database between 1999 and 2010. The study period
selected for the Italian mortality database was one-year
longer than the RNAIDS one to allow for the detection
of deaths for PWA diagnosed in 2009.
Specifically excluded from this analysis were: (1) PWA
who were non-Italian citizens, to limit false-negative re-
sults of the linkage due to non-Italian names and sur-
names (N = 3,184); (2) PWA who at time of death
resided or died in the provinces of Trento and Bolzano
because names and surnames were not reported in death
certificates (N = 167); 3) pediatric cases (i.e., aged less
than 13 years at AIDS diagnosis) (N = 48); 4) PWA with
coincident dates of AIDS diagnosis and death (N = 18).
Therefore, 14,552 adult Italian PWA constituted the
study group.
The main study outcome was death from any cause at
six months following AIDS diagnosis (i.e., these were
considered early mortality deaths), and it constituted the
focus of this analysis. Two statistical approaches were
used, a time-dependent, survival analysis and a logistic
regression analysis. For the survival analysis, we consid-
ered failure events the deaths for any cause that oc-
curred at 6 months, one, three, and five years after AIDS
diagnosis. Survival time was computed as the time
elapsed from the date of AIDS diagnosis to the date of
death (for PWA identified in the Italian mortality data-
base), to end of follow-up or to December 31, 2010 (i.e.,
censored cases) whichever came first. In addition to time
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trends in short-term survival (i.e., six months), we com-
puted data also for one, three, and five years survival fol-
lowing AIDS diagnosis to document temporal changes
in both short- and long-term mortality rates. The sur-
vival probability of PWA after AIDS diagnosis was esti-
mated by means of the Kaplan–Meier method [13]. To
identify factors reported at AIDS diagnosis potentially
associated to early mortality, odds ratios (ORs) and 95 %
confidence intervals (CIs) were computed using a multi-
variate logistic regression adjusted for variables that
were statistically significant at univariate analysis [13].
Results
Of the 14,552 PWA diagnosed between 1999 and 2009
included in this study, 5,706 were deceased as of
December 31, 2010. Of these 5,706 deaths, 2,757 (18.9 %
of all PWA) were early mortality deaths, i.e., they oc-
curred within six months after AIDS diagnosis. Over
time, the probability of surviving six months from AIDS
diagnosis increased from 81.2 % for cases diagnosed in
1999–2000 to 82.9 % (+2.1 %) for those diagnosed in
2009. Improvements were also registered for three- and
five-year survival (e.g., five-year survival increased from
60.7 % in PWA diagnosed in 1999-2000 to 65.4 % in
those diagnosed in 2005–2006, +7.7 %) (Fig. 1).
Table 1 reports the distribution of PWA and the
multivariate ORs for early mortality, according to se-
lected variables collected at AIDS diagnosis. The risk of
early mortality increased with age (OR = 5.28; 95 % CI:
4.41-6.32, for PWA aged ≥60 years vs. <35 years), and it
was similar in males and females. Geographical and so-
cioeconomic differences emerged, with PWA residing in
northern or southern Italy at higher risk for early mortal-
ity than PWA in central Italy. Less educated PWA (i.e.,
those with 5 or less years of education) were at higher risk
of death (OR = 1.25), and IDU showed a 71 % elevated risk
(95 % CI: 1.53-1.91) of early mortality than heterosexuals.
The risk of early mortality was lower (OR = 0.84, 95 % CI:
0.74-0.94) in PWA diagnosed in 2007–2009 vs. those diag-
nosed in 1999–2002. Conversely, an inverse association
emerged between early mortality risk and CD4 cell count,
particularly for PWA with a CD4 cell count lower than 50
CD4 cells/mm3 at AIDS diagnosis (OR = 1.87; 95 % CI:
1.55-2.27 vs. ≥350 CD4 cells/mm3). Use of cART before
AIDS was recorded in 36.2 % of these PWA (OR = 1.12;
95 % CI: 1.02-1.23 vs. untreated).
A CD4 count at AIDS diagnosis below 50 cells/mm3
was more frequently observed among PWA who ac-
quired HIV infection through heterosexual intercourse
(50.1 %), or homosexual male intercourse (42.3 %) than
among injecting drug users (33.8 %) (Chi-square test,
p < 0.01) (Fig. 2a). PWA who first tested HIV-positive
one month before AIDS had a significantly higher
proportion of low CD4 count (below 50 cells/mm3), as
compared to PWA who first tested HIV-positive seven
or more months before AIDS (56.7 % vs. 32.1 %,
Chi-square test, p < 0.01) (Fig. 2b).
The risk of early mortality was not affected by time
elapsed between first HIV-positive test and AIDS, even
after stratification for cART before AIDS (e.g., OR = 1.17,
95 % CI 0.73-1.86, for cART treated, and OR = 1.01, 95 %
CI 0.87-1.18, for untreated, 0–1 months vs. ≥13) (Table 2).
The number of defining conditions diagnosed at time
of AIDS was a strong, statistically significant, prognostic
Fig. 1 Six-month, one-, three-, and five-year survival probabilities of Italian people with AIDS by year at diagnosis. Italy, 1999–2009
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Table 1 Distribution of AIDS cases by selected characteristics collected at AIDS diagnosis and odds ratiosa for early mortality. Italy, 1999-2009
AIDS cases (No. = 14552) Early mortality (No. = 2757)
No. No. (%) OR (95 % CI)
Age at AIDS diagnosis (yrs)
13-34 2839 362 (12.8) 1b
35-39 3543 545 (15.4) 1.19 (1.03-1.37)
40-44 3305 597 (18.1) 1.48 (1.28-1.71)
45-49 1944 410 (21.1) 1.98 (1.69-2.32)
50-54 1104 253 (22.9) 2.38 (1.98-2.87)
55-59 764 181 (23.7) 2.59 (2.10-3.19)
≥60 1053 409 (38.8) 5.28 (4.41-6.32)
χ2 for trend (p-value) 373.13 (p < 0.01)
Gender
Male 11388 2203 (19.3) 1b
Female 3164 554 (17.5) 1.04 (0.93-1.16)
Area of residencec
Centre 3481 594 (17.1) 1b
North 8043 1534 (19.1) 1.14 (1.02-1.27)
South 2836 594 (20.9) 1.35 (1.19-1.54)
Education (yrs)
≥9 3563 563 (15.8) 1d
6-8 6603 1202 (18.2) 1.11 (0.99-1.24)
≤5 2127 519 (24.4) 1.25 (1.08-1.44)
Unknown 2259 473 (20.9) 1.23 (1.07-1.42)
χ2 for trend (p-value)d 9.57 (p < 0.01)
HIV transmission modee
Heterosexual intercourse 5088 887 (17.4) 1b
Homosexual male intercourse 2862 472 (16.5) 1.04 (0.91-1.19)
Injecting drug use 5646 1147 (20.3) 1.71 (1.53-1.91)
Year at AIDS diagnosis
1999-2002 6519 1255 (19.3) 1b
2003-2006 5084 965 (19.0) 0.92 (0.84-1.02)
2007-2009 2949 537 (18.2) 0.84 (0.74-0.94)
χ2 for trend (p-value) 8.79 (p < 0.01)
CD4 cell count/mm3 at AIDS diagnosisc
≥350 1135 140 (12.3) 1b
200-349 1623 286 (17.6) 1.45 (1.17-1.81)
50-199 5369 984 (18.3) 1.57 (1.29-1.90)
<50 5957 1187 (19.9) 1.87 (1.55-2.27)
χ2 for trend (p-value) 46.80 (p < 0.01)
Use of pre-AIDS antiretroviral drugsc
No 8834 1620 (18.3) 1b
Yes 5265 1005 (19.1) 1.12 (1.02-1.23)
aOdds ratios (OR) and 95 % confidence intervals (CI) estimated using multivariate logistic regression models adjusted for age, gender, area of residence, education,
HIV transmission mode, year and CD4 cell count at AIDS diagnosis
bReference category
cThe sum does not add up to the total because of missing values
dUnknown excluded
eThe sum does not add up to the total because of other, not considered, HIV transmission modes and missing values
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factor for early mortality. PWA with three or more
AIDS-defining diseases showed a 1.97-fold higher risk of
early mortality, compared to those with one disease
(Table 3). Elevated ORs for early mortality emerged, as
compared to those diagnosed with Pneumocystis carinii
pneumonia, for PWA diagnosed with non-Hodgkin
lymphomas, particularly primary brain lymphoma (OR =
11.66, 95 % CI: 7.32-18.57), and progressive multifocal
leukoencephalopathy (41.5 % of PWA with such disease
died within six months from diagnosis) (OR = 4.21, 95 %
CI: 3.37-5.27).
Discussion
Our population-based investigation focused on early
mortality of AIDS cases, and it showed that, over time, a
slight amelioration in the proportion of PWA who died
within six months from AIDS (from 81.2 % in PWA di-
agnosed in 1999–2000 to 82.9 % in 2009). Improvements
were also documented in five-year survival, from 60.7 %
in 1999–2002 to 65.4 % in 2005–2006. Our findings, to-
gether with the reduced risk of early mortality for PWA
diagnosed in more recent years that emerged from the
multivariate analysis, seemed to suggest a progress in
the management of AIDS that has led to a slight, but
clinically significant, improvement also in short term
survival. This latter encouraging observation is consist-
ent with findings reported elsewhere [14], and it prob-
ably reflects general improvements in the management
of comorbidities and non-HIV specific interventions, in
addition to enhancement of antiretroviral therapies [15].
Overall, the findings indicated that, 18.9 % of Italian
PWA, diagnosed between 1999 and 2009, died within six
months from AIDS diagnosis. This quantification of
early mortality risk is particularly high when compared
with findings from clinical trials [16]. It should be noted,
however, that this is a population-based descriptive in-
vestigation, including 40.9 % of PWA with less than 50
CD4 cell count at AIDS diagnosis in contrast, for
instance, with a median of 280 CD4 cell count at enrol-
ment in the cited trial [16]. In addition, and in agree-
ment with similar observations recorded in France [6]
and in Brazil [17], the results of this analysis strongly
indicated that the largest part of one year post-AIDS
mortality occurs within six months after diagnosis.
Approximately one fifth of Italian AIDS cases diag-
nosed between 1999 and 2009 were aged 50 years or
older, and older age was confirmed to be a strong nega-
tive prognostic factor also for early mortality. In this
study, the negative effect of older age on early mortality
was clear overall, after adjusting by CD4 cell count, HIV
transmission group, or other factors, or when stratifying
by time elapsed from first HIV-positive test to AIDS.
Fig. 2 AIDS cases distribution* by CD4 cell count/mm3 at diagnosis according to: a. HIV transmission mode; and b. Time elapsed between first
HIV-positive test and AIDS. Italy, 1999–2009, * 468 PWA with missing data on CD4 cell count were excluded
Table 2 Distribution of AIDS cases according to time from first
HIV-positive test and use of antiretroviral drugs and odds ratiosa
for early mortality. Italy, 1999-2009
Use of pre-AIDS antiretroviral drugsb
Yes No
Cases/deaths Cases/deaths
No./No. OR (95 % CI) No./No. OR (95 % CI)
Time from first HIV-positive test to AIDS diagnosis (months)c
0-1 113/25 1.17 (0.73-1.86) 4723/889 1.01 (0.87-1.18)
2-3 136/20 0.75 (0.46-1.24) 861/152 0.94 (0.75-1.17)
4-6 105/22 1.14 (0.69-1.86) 168/27 0.82 (0.53-1.28)
7-12 112/16 0.76 (0.44-1.31) 122/23 1.06 (0.66-1.72)
≥13 4600/874 1d 2435/433 1d
aOdds ratios (OR) and 95 % confidence intervals (CI) estimated using
multivariate logistic regression models adjusted for age, gender, area of
residence, education, HIV transmission mode, and year at AIDS diagnosis
bData on pre-AIDS use of antiretroviral drugs were not available for 337 cases
cInformation on date at first HIV-positive test was missing for 840 cases
dReference category
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This finding is in agreement with the results of a re-
cently published article showing that, in France, PWA
aged 60 years or more were at a nearly 3-fold higher risk
of late HIV presentation, and this event was strongly as-
sociated to an elevated risk of death in the first six
months after AIDS diagnosis [18].
Overall, women with AIDS, who constitute about 22 %
of Italian PWA included in this analysis, showed a risk of
early mortality similar to men. This result seems in line
with lack of gender difference reported in the proportion
of HIV late presenters in Italy [19], or life expectancy of
HIV-infected people on cART [14, 20]. It must be stressed
that a strong HIV prevention effort has been addressed to
women in recent years in Italy. National guidelines focus-
ing on HIV testing in pregnancy have been issued to avoid
mother-to-child transmission and, indirectly, to identify
unaware HIV-infected women [21].
Some of the characteristics herein investigated have
been previously recognized as risk factors for mortality
of PWA [7], namely injecting drug use, older age, a low
number of CD4 cells at AIDS diagnosis, and severe
AIDS-defining diseases. Nevertheless, some findings de-
serve to be highlighted.
In our study, the use of cART before AIDS was associ-
ated to a slight increased risk of early mortality (OR =
1.12). In Italy, cART is administered free of charge to
every HIV-infected individual fitting standardized clin-
ical and laboratory criteria [22]. In line with the litera-
ture, our results suggest that cART-treated individuals
benefit from a longer AIDS-free lifetime and that they
develop a full-blown AIDS when the immune suppression
is already at an advanced stage. Therefore, the risk of early
mortality in the pre-AIDS treated group was related to the
final depletion of the immune system and/or the presence
of other life threatening conditions. Moreover, this finding
may also be due to channelling bias (i.e., treated people
are those with the worse prognosis) and/or to the pres-
ence of unmeasured confounding factors.
The type of AIDS-defining disease turned out to be a
strong negative prognostic factor for early mortality.
Among these, non-Hodgkin lymphomas and multifocal
leukoencephalopathy were associated to more than 3-fold
Table 3 Distribution of AIDS cases according to AIDS-defining diseases and odds ratiosa for early mortality. Italy, 1999-2009
AIDS cases Early mortality
No. No. (%) OR (95 % CI)
AIDS-defining diseasesb
Infectious diseases
Pneumocystis carinii pneumonia 2650 393 (14.8) 1c
Tuberculosis 1089 126 (11.6) 0.81 (0.65-1.00)
Candidiasis 2943 404 (13.7) 0.84 (0.72-0.98)
Recurrent pneumonia 466 62 (13.3) 0.91 (0.68-1.23)
Other infections 1476 266 (18.0) 1.22 (1.02-1.45)
Brain toxoplasmosis 856 175 (20.4) 1.43 (1.16-1.75)
Neoplasms
Invasive cervical cancer 104 9 (8.7) 0.59 (0.29-1.24)
Kaposi sarcoma 773 80 (10.4) 0.82 (0.63-1.07)
Immunoblastic lymphoma 707 234 (33.1) 3.18 (2.59-3.89)
Burkitt lymphoma 286 95 (33.2) 3.48 (2.62-4.62)
Primary brain lymphoma 85 54 (63.5) 11.66 (7.32-18.57)
Other conditions
HIV encephalopathy 999 231 (23.1) 1.55 (1.28-1.88)
HIV wasting syndrome 1655 436 (26.3) 1.78 (1.52-2.09)
Progressive multifocal leukoencephalopathy 463 192 (41.5) 4.21 (3.37-5.27)
No. of AIDS-defining diseases at diagnosis
1 11670 2048 (17.6) 1c
2 2261 510 (22.6) 1.27 (1.13-1.42)
≥3 621 199 (32.1) 1.97 (1.64-2.37)
aOdds ratios (OR) and 95 % confidence intervals (CI) estimated using multivariate logistic regression models adjusted for age, gender, area of residence, education,
HIV transmission mode, year and CD4 cell count at AIDS diagnosis
bFor patients with more than one AIDS-defining disease, only the most severe was considered
cReference category
Suligoi et al. BMC Infectious Diseases  (2015) 15:229 Page 6 of 8
higher ORs, similarly to what reported in other
population-based and clinical studies conducted in several
high-income countries [20, 23].
Finally, IDU showed the highest early mortality risk
compared to PWA who acquired the infection through
sexual contact; however, among IDU we observed the low-
est proportion of individuals with a low CD4 cell count,
suggesting that the elevated risk of early mortality was, in
this group. mainly attributable to a longer duration of HV
infection and/or to comorbidities, such as liver diseases or
cancer, rather than to immune suppression.
The main strengths of this population-based, retrospective-
cohort study are the national coverage for both AIDS noti-
fications data and death certificates; the quality of data, in
terms of completeness and representativeness; the large
size of the study population; and the long observation
period. It is relevant to mention that the linkage between
the two independent databases allowed the detection of all
PWA who died for any reason, and not only for AIDS-
related conditions, without the inconvenience of losses to
follow-up that can occur in cohort studies based on a
unique data source. However, we are aware that prospect-
ive cohort studies, in comparison with retrospective ones
could provide a larger set of information and a more pre-
cise assessment of follow-up time for the survival analysis.
Conversely, a major study limitation is the exclusion of
non-Italian PWA from the analysis whose contribution
to the AIDS epidemic in Italy is relevant. However, the
linkage methodology used in this study –despite taking
into account frequent spelling errors in names– could
be less sensitive when matching foreign names and
surnames due to a higher inaccuracy, in addition to a
higher tendency of foreign citizens to migrate. Informa-
tion on date of HIV-seroconversion is not collected by
RNAIDS, as well as duration of adherence to treatment
with cART; therefore, the duration of HIV infection of
PWA and major parameters of treatment with cART
could not be used for the aims of this investigation.
Moreover, data on post-AIDS use of cART are not
available at the RNAIDS, and this represents another
important limitation that could have concealed the
impact of cART on short term mortality.
Conclusions
In the full cART era, population-based investigations
focusing on the mortality of PWA and on prognostic
factors represent valuable pieces of epidemiological
evidence for clinicians and for researchers alike. These
study results indicated that, in Italy, about one fifth of
PWA died within six months after AIDS diagnosis, and
this early mortality risk slightly decreased in the last
decade. The main risk factors of early mortality were
older age, use of injection drugs, a very low CD4 cell
count and the presence of a number of life threatening
conditions at AIDS diagnosis. These findings indicate
the need for enduring and ameliorating preventive ac-
tions aimed at timely HIV testing among all individuals
at risk for HIV infection and/or those who present dis-
eases known to be related with HIV infection.
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